Schering-Plough HIV Drug Linked to Cancer in Mid-Stage Study
Posted on: Monday, 6 March 2006, 12:00 CST
Schering-Plough has revealed that five patients treated with the company's HIV drug candidate vicriviroc in a phase II trial have developed cancer.
Vicriviroc is an investigational CCR5 receptor antagonist currently being evaluated by the NIH-sponsored Adult AIDS Clinical Trials Group (ACTG) in an ongoing phase II clinical study of 118 treatment-experienced HIV patients in the US. Patients who entered this trial were heavily treatment experienced with advanced HIV disease and low CD4 counts.
The ACTG study monitoring committee for this trial has informed the ACTG and Schering-Plough that five cases of malignancy have been observed in patients treated with vicriviroc. The five cases included four patients with lymphoma and one patient with gastric adenocarcinoma (stomach cancer).
The ACTG has concluded that a causal association between vicriviroc and the lymphoma cases could not be established at this time. The ACTG further concluded that, since vicriviroc, at the two highest doses tested, together with an optimized background antiretroviral regimen showed evidence of virologic activity and CD4 count increases, the trial will continue.
Patients and investigators in the trial are immediately being informed of these results. The ACTG is taking additional measures to assure the safety of patients in the trial. These include introducing long-term follow-up and unblinding the patients in order that they and their physicians may make a more informed decision about their treatment options.
Schering-Plough said that it intends to continue to work closely with the ACTG as well as the FDA and other health authorities to fully determine the potential role of vicriviroc in HIV therapy.
Source: Datamonitor
Related Articles
- Biovitrum and Syntonix Dose First Hemophilia B Patient in Clinical Trial of a Novel Factor IXFc Treatment
- BARACLUDE(R) (Entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-Naive Chronic Hepatitis B Patients
- ZIOPHARM Treats Patients in U.S. Phase I Trials of Oral Darinaparsin and Indibulin
- Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
- Accentia Biopharmaceuticals Updates Interim Analysis of Blinded Clinical Results in the Fast-Tracked Pivotal Phase 3 Trial of SinuNase for the Treatment of Refractory Chronic Sinusitis
- TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
- S. China Province Reports Increasing HIV/AIDS Cases
- Toman's Tuberculosis: Case Detection, Treatment and Monitoring - Questions and Answers
- TorreyPines Therapeutics Initiates Phase I Clinical Trial of NGX267 for the Treatment of Alzheimer's Disease
- Global HIV/AIDS Cases Rising for Women
 |
 |
User Comments (0)
RSS Feeds